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 Duchenne muscular dystrophy is a progressive neurodegenerative muscle disease 
that makes the patients wheelchair-dependent around the age of 12 and eventually causes 
death in the late twenties due to lung and/or heart failure. A functional dystrophin is absent 
in DMD patients which makes their muscle cells prone to physical damage by every single 
movement. A homolog of this fundamental protein is utrophin which is known to be able to 
partially compensate for the lack of dystrophin. Hence, up-regulation of this protein has 
been promising for years as a strategy to improve this disorder. It has been repetitively 
proved that this approach could be achievable via stimulation of calcineurin/NFAT signalling 
pathway which in turn promotes the oxidative capacity of the muscle. Also, pharmacological 
induction of the Adenosine monophosphate - activated protein kinase pathway can provoke 
the slow oxidative myogenic program. Nevertheless, recent evidence shows the capability of 
the Heat Shock Protein 70 to ameliorate the dystrophic phenotype by preserving the 
function of sarco/endoplasmic reticulum Ca2+ ATPase channels independent of utrophin. 
Thus in this study, we sought to shed light on the underlying mechanisms by which 
intracellular Ca2+ oscillations coordinate with calcineurin/NFAT signalling in these adaptive 
responses. Our data suggest an inhibitory effect of AMPK activators on calcineurin activity 
and further prove the independence of HSP70 regulation from the calcineurin /NFAT 
pathway. Moreover, we were able to represent a more detailed understanding of the way 
Ca2+ handling proteins determine the activity rate of calcineurin in response to altered 
cytosolic Ca2+ oscillations. Collectively, our results may bring the scientific community one 
step closer to finding a comprehensive approach to cure or improve the dystophic disorders 
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1.1 - DUCHENNE MUSCULAR DYSTROPHY 
 Duchenne muscular dystrophy (DMD) is a progressive neurodegenerative muscle 
disease caused by a recessive loss of function mutation in the dystrophin gene located on 
the short arm of X chromosome1,2. Each year, one in 3600-6000 newborn males are 
diagnosed for this disorder. Individuals with DMD begin to show symptoms earliest at the 
age of three, become wheelchair dependent at around the age of 12 and eventually die in 
their late twenties due to lung and/or heart failure2,3. Several redundant approaches to 
amend the severity of the disorder have been developed, yet no cure or effective treatment 
has been reported though. 
1.1.1 - DMD Etiology 
 In DMD cases, the gene coding for the 427 kDa dystrophin protein is mutated 
resulting in either a truncated small non-functional protein or the deletion of the gene4,5. A 
full length skeletal muscle isoform of dystrophin protein is made up of four domains 
including an N-terminal actin binding domain, a rod domain, a cysteine-rich domain, and a 
carboxyl-terminal domain6. 
 This large cytoskeletal protein associates with various proteins to form 
the dystrophin-associated protein complex (DAPC) which provides a link between the 
muscle membrane and the actin filaments (Fig. 1)2. In other words, it links the extracellular 
matrix to the intracellular microfilament network. This is crucial for the stability and 
integrity of the membrane during contraction and relaxation of muscle7. Accordingly, lack of 
dystrophin in DMD patients results in a leaky membrane that causes muscle cells to be 
replaced by adipose and scar tissue8,9. This along with degeneration of muscle fibres makes 
the muscle non-resistant to mechanical pressure produced by walking and as a result 
exacerbates the status of the disease as it progress10-12. 
 In molecular medicine, there are three known markers for diagnosis of muscle 
damage. First, and the most common, is the increase of muscle creatine kinase levels in the 
blood (serum) of patients who are developing a muscle myopathy due to the efflux from the 
leaky sarcolemma13-15; secondly is central localization of muscle nuclei, and thirdly is the 














Fig. 1 The schematic structure of the dystrophin-associated protein complex (DAPC)- (adapted from2). Using 
its N-terminal actin binding domain, the large dystrophin protein links the actin filaments to the membrane. 
1.1.2 - The mouse model for DMD 
 In 1983 a group of researchers announced that using enzyme assays they had found 
a spontaneous mutation arisen in their inbred C57BL/10 colony of mice after 5 generations.  
This mutation had caused a significant increase in serum levels of protein kinases such as 
creatine kinase and pyruvate kinase indicative of potential muscle damage17. This was 
confirmed by the presence of centrally localized nuclei showed by hematoxylin and eosin 
stained muscle cross sections. Finally, the mutated gene (i.e. dystrophin), was located on 
the X chromosome by positional cloning17. Later on, the sequence of dystrophin cDNA from 
normal and mutated mice revealed that a point mutation in mouse mdx gene resulted in a 
termination codon which prematurely stops the translation18.    
 The mice from this model of DMD, which are named mdx, are histologically normal 
early after birth, but after 3-4 weeks of development they begin to develop cell and 
molecular abnormalities similar to those in DMD patients19-21. A study on mdx mice showed 
a reduction of their life span compared to wild-type mice, resembling the DMD cases 
regardless of the fact that mdx mice never lose ambulation22.  
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1.1.3 - DMD treatment strategies 
 Glucocorticoids such as prednisone and deflazacort have been conventionally used 
to treat DMD for about 50 years23 and remain clinically the most beneficial treatment for 
the patients due to their ability to improve muscle strength by delaying the rapid  
progression of muscle weakness and as a result rendering the patients more ambulatory up 
to approximately two years24. There is still no consensus about the exact mechanism of 
action of these steroids. Some researchers suggest that glucocorticoids bind to their 
receptors and trigger a cascade of pathways that eventually inhibit inflammatory factors 
such as NF-ĸB, therefore reducing fibrosis25. Other studies show that corticoids can induce 
myoblast proliferation by up-regulating insulin-like growth factors and therefore increase 
muscle fibre regeneration26. In_vitro studies have shown that utrophin, the homologue of 
dystrophin, can be either up-regulated or stabilized by corticoid treatment at both 
transcriptomic and preoteomic levels27.  
 There is also the exon skipping technique that attempts to bring the out of frame 
dytrophin gene sequence in frame so that a smaller but functional dystrophin can be 
translated28. However, there are many clinical and theoretical issues with that, spanning 
from hurdles of the delivery route of the anti-sense oligonucleotides to the need of 
personalized and mutation-specific production of such oligonucleotides2. 
1.2 - Utrophin up-regulation 
 Utrophin is the autosomal homologue of Dystrophin which shares highly similar 
structure (i.e. 80% identical protein sequence) and function29. The N-terminal domain of 
utrophin contains an actin-binding site and therefore may compensate for the absence of 
dystrophin30,31. During the early stages of differentiation and development of an embryo, 
the two isoforms of utrophin are expressed prior to dystrophin, encompassing muscle cells 
membrane (utrophin-A) and blood vessels (utrophin-B). But as the embryo matures, 
utrophin-A is substituted by dystrophin and disappears or gets restricted to neuromuscular 
junctions32. DMD patients show higher levels of utrophin (Fig. 2)4 and that was the start 










Fig. 2 The expression of utrophin in DMD vs normal- (adapted from4). Cross-sections of the muscles of DMD 
and normal human stained for dystrophin and utrophin shows significantly higher levels of utrophin in DMD. 
As it could be seen, when dytrophin is present (i.e. normal healthy) utrophin is expressed in very low levels.    
 
1.2.1 - Fibre-specific expression of utrophin 
 Skeletal muscles are composed of four types of fibres among which three are type 2 
fast glycolytic and one is type 1 slow oxidative33. Soleus muscle is predominantly made up of 
type 1 slow fibres ranging from 64 to 100 percent (the other being type 2a fibres)34. It is 
revealed that utrophin protein levels are 3 to 4 times higher in soleus compared to the fast 
extensor digitorium longus (EDL) muscle indicating that utrophin expression in skeletal 
muscles is specific to slower more oxidative fibres35. However, the level of utrophin 
transcripts in soleus is almost equal to that in EDL. The reason why soleus muscles tend to 
have more utrophin protein is that utrophin transcripts are more stable in oxidative fibres, 
ranging from minutes to days35. Since utrophin levels are also higher in DMD patients than 
healthy individuals, as mentioned previously, strategies that aim to up-regulate utrophin 
levels predominantly involve promoting the transition of muscle fibres from a faster more 
affected, to a slower, more resistant phenotype through pathways that regulate the 




1.2.2 - Calcineurin-NFAT signalling pathway 
 Calcineurin (Cn)-mediated Nuclear Factor of Activated T-cell (NFAT) signalling is 
primarily known for its crucial role in immune system responses. As a result of high levels of 
intracellular calcium ([Ca2+i]), calmodulin binds Ca2+ ions, undergoes conformational changes 
which let it interact with the phosphatase protein Cn (Fig. 3)37,38. As a result of this 
interaction, Cn is activated which in turn de-phosphorylates NFAT thereby causing it to 
translocate into the nucleus where it promotes the transcription of cytokines37. Certain 
kinases such as creatine kinase 1 and Glycogen Synthase Kinase 3 Beta (GSK3β) can reverse 
this translocation by further phosphorylating NFAT39. Cn can be inhibited by regulator of Cn 









       
Fig. 3 An outline of the Cn signalling pathway- (adapted from38). Interaction of the Ca2+-activated calmodulin 
with Cn, activates Cn and therefore de-phosphorylates NFAT causing it to migrate in to the nucleus where it 
can initiate the transcription of multiple of genes including RCAN. Activation of NFAT and Cn can be inhibited 
by GSK-3 and RCAN, respectively.      
 In skeletal muscle, the promoter of the genes that are part of the oxidative myogenic 
program possess binding sites for NFAT proteins indicating the involvement of Cn as a key 
contributor to fibre type specification41. In support of this, it was shown that treating mice 
RCAN 
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with pharmacological Cn blockers such as Cyclosporin-A (CsA) and FK506 could induce slow-
to-fast fibre transformation41.  
Electrophoretic mobility shift assay followed by supershift assay experiments have revealed 
the existence of NFAT binding sites on the promoter of utrophin-A42. In light of that, 
introduction of an activated form of Cn (CnA*) to mdx mice increased the expression of 
utrophin-A introducing a novel method to strategies aimed for up-regulation of utrophin43.  
1.2.3 - AMPK signalling pathway 
 Adenosine monophosphate-activated protein kinase (AMPK) is one of the enzymes 
that can sense and restore the energy levels of the cell in response to energy homeostasis-
related signals44. Many studies have shown that chronic stimulation of AMPK can trigger the 
expression of mitochondria biogenesis biomarkers (e.g. PGC-1α) indicative of the promotion 
of the slow myogenic program45-47. Since AMPK has such a potential, it wouldn't be 
improbable that utrophin expression eventually increase too. Accordingly, in 2011 it was 
shown that utrophin was up-regulated in parallel with the augmentation of slow myogenic 
markers when mice were chronically treated with the AMPK activator 5-aminoimidazole-4-
carboxamide-1-β-D-ribofuranoside (AICAR)48. Additionally, in_vitro and in_vivo 
administration of the type 2 diabetes treatment drug Metformin (MET), have been shown to 
elevate utrophin-A levels (unpublished data) and promote the oxidative program through 
AMPK pathway49.  
1.3 - Intracellular calcium ([Ca2+]i) handling in DMD 
 [Ca2+]i of skeletal muscle cells are known to be increased in DMD50,51. Sub-cellular 
Ca2+ localization studies on DMD have elucidated significant higher cytosolic Ca2+ 
concentration52,53. Further detailed studies on mdx mice revealed that this concentration of 
Ca2+ is predominantly restricted to the sub-sarcolemma region of myotube cells54,55. As 
mentioned previously, lack of dystrophin in DMD cases makes the muscle cell membrane 
susceptible to rupture during muscle contraction, leading to a leaky membrane. Accordingly, 
the elevation of [Ca2+]i is first and foremost attributed to this incident whereby Ca2+ leak 
channels are activated and consequently a large flow of Ca2+ is allowed to enter the 
cytosol56. This abnormal cytosolic concentration of [Ca2+]i leads to permanent but transient 
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cycles of Ca2+ uptake and release by Ca2+ handling channels of the sarcoplasmic reticulum 
(SR). Moreover, high concentrations of [Ca2+]i triggers the activation of a series of proteins 
that could be both beneficial (e.g. activation of Cn/NFAT signalling) and harmful (e.g. 
activation of certain proteinases) for the cell57-59.  
 Ca2+ channels of SR consist of ryanodin receptor (RYR) Ca2+-release channel and 
Sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) Ca2+ uptake channel. These channels are 
normally inhibited by sarcolipin (SLN) and phospholamban (PLN)60. Whenever the calcium 
equilibrium is skewed, these proteins get phosphorylated by protein kinase A (PKA) and B 
(Akt), lose their inhibitory effect, and as a result lead to opening of the channels61. Some 
studies on mdx mice have shown the reduced ability of muscle cells to remove the excessive 
cytosolic Ca2+ introduced during contraction, indicating potential malfunction of SERCA 
channels as an important factor62. Accordingly, several recent studies aiming at amelioration 
of the dystrophic phenotype have drawn their attention towards promoting the function of 
these channels63 and in general deciphering the complex mechanism of  Ca2+ handling to re-
stabilize the Ca2+ homeostasis64,65.  
1.3.1 - Heat shock protein as a chaperon for SERCA 
 As the name indicates, heat shock proteins (HSPs) are a group of proteins that are 
mainly regulated in response to environmental stress particularly heat shock66. Different 
isoforms of these proteins are usually named based on their polypeptide size ranging from 
10 to ~ 100 kDa67-69. Among various functions that are reported for HSPs, they are best 
known for their chaperone activity69-71. This characteristic of HSPs has shown its capacity to 
interact with and ameliorate the function of cytoskeletal proteins such as actin68,72 and the 
SR Ca2+ pump SERCA63. The latter finding is of a great importance since Ca+ homeostasis is 
disrupted in DMD. Accordingly, a group of scientists in Australia showed that induced 
expression of HSP70 either genetically or pharmacologically can improve and maintain the 
function of SERCA and consequently highly mitigate the dystrophic phenotype without the 
need for utrophin (Fig. 4)63. This is a breakthrough finding in DMD research for its 
independence from utrophin, the protein that has been a focal point of research in the field 
for more than 30 years. In addition to phenotypic improvements, augmentation of HSP70 







     
 
Fig. 4 Overexpression of HSP70 ameliorates the dystrophic phenotype (adapted from63). Pharmacological 
induction of HSP70 expression in utrophin-dystrophin double knock-out mdx mice (mdx DKO) significantly 
decrease the spinal curvature, the main phenoypical marker of DKO mice. This amelioration is independent of 
utrophin since DKO mice are null for this gene.    
 
1.3.2 - The calcium buffering protein Parvalbumin 
 Parvalbumin (PV) is an intracellular high affinity Ca2+-binding protein specifically 
expressed in fast fibres and found at higher levels in DMD fast fibers than normal73. It has 
the ability to buffer the sudden cytosolic Ca2+ level rise therefore bringing back the muscle 
to its relaxation state74. Slow fibre forced expression of PV in wild-type mice reduces the 
oxidative capacity of the muscle and is linked to changes in Cn/NFAT signalling pathway75. 
However, fibre type composition of the muscle is not changed indicating the possibility of 
involvement of other Ca2+ - dependent regulatory pathways75. To further investigate the 
role of PV in skeletal muscle, it is reasonable to also examine the alterations of Cn/NFAT in 
mdx mice overexpressing PV and comparing it to the mice that, in contrast, overexpress the 
constitutively active Cn (CnA*). Utrophin as a marker for Cn/NFAT signalling alterations and 
HSP70 as a chaperon for Ca2+ handling proteins can be good candidates for this comparison. 
Additionally, searching for probable Cn/NFAT signalling changes in mdx mice by 
administration of the drugs which are known to promote the oxidative capacity through 
AMPK pathway can also open a new window to our understanding of the molecular 
interplay mechanisms between Cn/NFAT signalling pathway and Ca2+ homeostasis.                    
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2. HYPOTHESIS AND SCIENTIFIC RATIONAL 
2.1- Scientific rational of this project 
 In order to get better insight into the intracellular mechanism by which Ca2+ 
homeostasis is regulated in coordination with the Cn/NFAT signalling pathway and in 
response to changes in oxidative capacity of the skeletal muscle fibres in dystrophic 
conditions, three concomitant approaches were adapted. To fulfill the requirements of such 
an experiment, mdx mice expressing either constitutively active Cn (CnA*) or slow-fibre 
force-directed Ca2+ buffering protein Parvalbumin (PV) were generated by crossing mdx 
mice with CnA* and PV transgenic mice. Promotion of the slow fibre program was also 
triggered in another group of mdx mice by pharmacological administration of AICAR and 
Metformin, which are known to provoke this triggering through stimulation of the AMPK 
pathway. Therefore, having three different experimental models that all share the 
substantial need for regulation of intracellular Ca2+ homeostasis in response to different 
triggers can potentially give us a more profound understanding of the coordination status 
between Cn/NFAT signalling and the Ca2+ handling channels of the sarcoplasmic reticulum. 
2.2 - Hypothesis 
 The quantity and activity of SR calcium-handling proteins can alter the Cn/NFAT 
signalling and potentially other known or unknown Ca2+ dependent pathways in dystrophic 
myopathy.  
3. Specific aims 
3.1 - Aim 1 
 To examine how the treatment of mdx mice with AICAR and Metformin (two drugs 
that stimulate the AMPK signalling pathway) alter Cn/NFAT signalling in mdx mice. 
3.2 - Aim 2 
 To impose a fast fibre-specific Ca2+ metabolism condition on slow fibres by directing 
the expression of PV into the slow fibres of mdx mice (i.e. generation of mdx/PV mice). 
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3.3 - Aim 3 
 To make the Cn/NFAT signalling constitutively active in fast fibres by directing the 
expression of CnA* into the fast fibres of mdx mice (i.e. generation of mdx/CnA*) 
3.4 - Aim 4 
 To assess the regulation of Ca2+ handling proteins of SR in response to imposed Ca2+ 
homeostasis and Cn/NFAT signalling alterations in mdx mice (i.e. mdx/PV and mdx treated 
mice).  
3.5 - Aim 5 
 To evaluate the expression status of the chaperon of SERCA channels (i.e. HSP70) in 
mdx, mdx/PV and mdx/CnA* mice. 
4. METHODS 
4.1 - Animal care  
 All animal care and handling was administrated according to the guidelines and 
protocols of the Canadian Council of Animal Care. These protocols had been approved by 
the University Animal Research Ethics Committee (UAREC). Male transgenic mice less than 
six month old expressing either PV or CnA* were crossbred with similarly aged male mdx 
mice. The presence of the transgenes was confirmed by Polymerase Chain Reaction (PCR) 
on the genomic DNA of the mice, which was extracted from their tail tissue. The identity of 
wild-type, PV, mdx, and mdx-cross-bred mice was also detected in the same fashion. The 
sleeping quarters of the mice were consecutively kept under a twelve-hour daylight cycle.       
4.2 - Mice genotyping 
 Mice were genotyped as described previously by Chakkalakal, Chin, and Shin75-77.  
Briefly, ~ 5mm of the mice’s tail tips were clipped and subjected to over-night incubation 
with 500 µl standard tail digestion buffer containing 4 µl proteinase K. The following 
morning, DNA was extracted with the conventional phenol-chloroform-based DNA isolation 
method. Appropriate primers were used to amplify each relevant loci by PCR (Table 1). 
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Amplicons were then electrophoresed on a 1.5 % agarose gel containing ethidium bromide 
and later exposed to UV-light to visualize stained DNA.          
4.3 - Animal surgeries and muscle extraction 
 Mice of 10-12 weeks old were anesthetized and the soleus (Sol), gastrocnemius 
(Gas), tibialis anterior (TA), and extensor digitorum longus (EDL) muscles of both legs were 
harvested in the surgery room of Concordia University animal facility. For biochemical 
procedures, muscles were weighed and rapidly flash-frozen in liquid nitrogen. For 
histochemical procedures, muscles were weighed, embedded by commercial optimal 
cutting temperature (OCT) compound, frozen in a pool of cool melting isopentane 
surrounded by liquid nitrogen-frozen isopentane, and then dropped into the liquid nitrogen. 
These samples were then transferred into -80 C degree ultra-freezers until use.                
4.4 - AICAR and Metformin treatment of mice 
 Drug treatments and corresponding mice tissue extractions were carried out in the 
lab of Dr. Bernard Jasmin with the approval of the University of Ottawa, and in accordance 
with Canadian Council of Animal Care guidelines. Protocol and treatment dosage are 
described previously by Ljubicic48,78. Briefly, mdx mice three to four weeks old were treated 
with AICAR (500 mg/kg/day) once a day by subcutaneous interscapular injections for 24-30 
days, and with Metformin 5 mg/L in the drinking water for six weeks48,79.    
4.5 - Protein extraction and Immunoblotting 
 Frozen muscles were pulverized in liquid nitrogen using mortar and pestle. 
Pulverized tissue was homogenized in sufficient volumes (i.e. 12-15 µl x the weight of the 
muscle in mg) of a protein extraction buffer comprised of 75 mM Tris pH 6.8, 3.8% SDS, 4 M 
urea, 20% (vol/vol) glycerol, and Roche cOmplete Mini Protease Inhibitor cocktail for one 
hour on ice, along with short vortexes from time to time.  Samples were then heated for 
two minutes at 95 ͦC degrees, followed by centrifugation at 2000 x g for 15 minutes. 
Afterwards, supernatants were collected and the protein concentration of each sample was 
measured using the Bradford assay (Bio-RAD). Either 20 or 25 µg amounts of proteins were 
then resolved by electrophoresis on either 5% Tris-Glycine polyacrylamide gels for high 
molecular weight (HMW) proteins at 130 V for 1.5-2 hours, or 7% Tris-Tricine 
 12 
polyacrylamide gels for low molecular weight (LMW) proteins at 100 V for 1-1.5 hours. Once 
the run was complete, gels were transferred to nitrocellulose membranes overnight at low 
constant amperage (i.e. 50 mAmps for HMWs and 150 mAmps for LMWs). On the second 
day, transfer efficiency was checked by Ponceau and then after, membranes were blocked 
in either Blotto (i.e. 5% w/v non-fat milk, 0.1% tween (T) in phosphate-buffered saline (PBS) 
or in 1-3% Bovin Serum Albumin (BSA) in 0.1% T/PBS buffers for one hour at room 
temperature, followed by incubation with titrated concentration of proper primary 
antibodies (Table 2) in the blocking buffer overnight in a cold room (4 C degrees) on a Belly 
Dancer shaker. On the third day, membranes were washed 3 x 10 minutes each by 0.1% 
T/PBS, followed by incubation in horseradish peroxidase (HRP) - conjugated anti-mouse or 
anti-rabbit secondary antibodies for 1-1.5 hours at RT. After 3 x 10 minute washes with 0.1% 
T/PBS, membranes were incubated with enhanced chemiluminescence (ECL) reagent (EMD 
Millipore) for five minutes in the dark, then exposed using the Alpha Innotech FlourChem 
imaging system.                              
4.6 - Quantification and statistical analysis 
 The band intensity of each blot was quantified using either the FlourChem image 
analysis software or the NIH Image J program. Each target was normalized to its 
corresponding loading control (e.g. alpha-tubulin or Vinculin). The standard deviation of 
each group (n=3) was considered, and student's t-test was used to compare each two sets 
of data (e.g. mdx vs mdx/PV or WT vs PV).  
Mouse of 
question 































Table 1. Detailed list of the primers that were used to genotype the transgenic animals. 
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Target protein Supplier and product # Antibody dilution Detection size (kDa) 
Utrophin Novocastra leica #NCL-DRP2 1:500 in 1% blotto 395 
NFATc1 Santa Cruz #sc-13033 1:500 in 1% BSA 90-140 
Calcineurin Cell signaling #2614 1:1000 in 5% blotto 60 
p-GSK3β Cell signaling #9322 1:3000 in 3% BSA 46 
GSK3β Cell signaling #9315 1:3000 in 3% BSA 46 
p-Akt Cell signaling #4051 1:1000 in 3% BSA 60 
Akt Cell signaling #9272 1:1000 in 3% BSA 60 
Alpha-tubulin Cell signaling #2125 1:2000 in 5% blotto 52 
Vinculin Sigma #V9131 1:5000 in 5% blotto 116 
RCAN1 Sigma #D6694 1:5000 in 2% blotto 26 and 38 
Ryanodin receptor 1 (RYR1) Thermo #MA3-925 1:500 in 1% blotto 565 
SERCA1 Thermo #MA3-912 1:7500 in 3% BSA 110 
SERCA2 Thermo #MA3-919 1:1000 in 3% BSA 110 
Phospholamban Thermo #MA3-922 1:500 in 1% BSA 6 and 28 
HSP70 Enzo #SPA-812 1:1000 in 1% blotto 70/72 
Sarcolipin EMD Millipore #ABT13 1:500 in 5% blotto 6 
Table 2. Detailed list of antibodies and their dilution for immunoblotting experiments. 
 
5. RESULTS 
5.1 - Administration of AMPK activator drugs, AICAR and Metformin, has an inhibitory effect 
on Cn/NFAT signalling 
 Our collaborators (Bernard Jasmin's group, University of Ottawa) have shown that 
chronic treatment of mdx mice with AICAR up-regulates the markers of slow-oxidative 
myogenic program and utrophin, the compensator for the absence of dystrophin in DMD, 
through an AMPK pathway45. They have also managed to show similar effects for Metformin 
(unpublished data). However, they have not examined possible alterations in the Cn/NFAT 
signalling pathway. Therefore, we decided to analyze the muscle proteins of the same 
treated mice for Cn/NFAT signalling to see if this pathway also plays a role in their findings. 
EDL, the very fast muscle which was used for their study, was not available anymore. 
Therefore, we sufficed with gastrocnemius, which has a mixture of all possible fibres, 
including pure and hybrids. We first examined the phosphorylation status of GSK3β by 
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acquiring the ratio of phosphorylated to total GSK3β, and observed that it was lower under 
those treatments compared to the mdx vehicle mice (Fig. 5B).  
Fig. 5 Chronic activation of AMPK pathway decreases the markers of Cn activity. Representative immunoblot 
and quantification for A-B) phosphorylated GSK3β over total GSK3β, C-D) NFATc1 E-F) Cn, G-H) RCAN1.4, and I-
J) utrophin protein levels in the Gas muscle of WT, mdx Veh, mdx AICAR and mdx Met mice. Relative quantities 
are normalized to either alpha-tubulin or vinculin (n=3; P<0.05). *compared to mdx Vehicle. ±STDEV are 
shown. 
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This means a less active form of GSK3β, which may happen when there are less NFAT to be 
shuttled to the nucleus. To examine this hypothesis, we probed for the main isoform of 
NFAT (i.e. NFATc1) and observed decreased expression of this protein in mdx mice treated 
with AICAR and Metformin compared to the mdx vehicle mice (Fig. 5D). These were the 
initial signs of decreased Cn/NFAT signalling. The next step was to investigate the expression 
of Cn and its inhibitor RCAN1.4 (the skeletal muscle isoform of RCAN). Interestingly, we 
observed no changes in RCAN1.4 and Cn (Fig. 5H), which could bring us one step closer to 
believe that Cn activity is reduced. To further prove this strong probability, we investigated 
the expression of utrophin, which directly undergoes significant alterations by the 
augmentation or inhibition of Cn activity. As expected, the utrophin content was decreased 
in both cases to a level similar to that in wild-type (Fig. 5J).  
 Intracellular Ca2+ kinetics are controlled by the Ca2+ release and uptake pumps of 
sarcoplasmic reticulum’s lumen. More activity of uptake pumps or less activity of release 
pumps can determine the cytosolic levels of Ca2+. Alterations in the activity of Cn correlates 
with the cytosolic Ca2+ concentration. Thus, we next examined the expression and activity of 
these Ca2+ channels in order to be able to justify the observed reduction of Cn/NFAT 
signalling. We did not see any changes in the expression of the fast and slow isoforms of 
SERCA (i.e. 1 and 2 respectively) uptake channels or the ryanodin receptor 1 release 
channels (Fig. 6B-D). However, sarcolipin, the inhibitor of SERCA channels, was highly 
reduced (Fig. 6E), indicating more activity in the uptake channels and less available cytosolic 
Ca2+ as a result. The phosphorylation of sarcolipin is predominantly done by Akt, and 
therefore, less expression of sarcolipin should correlate with a reduced ratio of the 
phosphorylated Akt over the total Akt. Our data confirms this fact (Fig. 6F). 
5.2 - Overexpression of the Ca2+ buffering protein, parvalbumin, leads to down-regulation of 
utrophin 
 For years, our lab has repeatedly shown that changes in Cn/NFAT signalling directly 
correlates with changes in utrophin expression7,42,43. Here in this study, we sought to test 
the hypothesis that changes in the upstream of the Cn/NFAT pathway will also affect the 













Fig. 6 Calcium uptake channels are less inhibited by chronic activation of AMPK pathway. Representative 
immunoblot (A) and quantification for B) RYR1, C) SERCA1, D) SERCA2, E) SLN, and F) phosphorylated Akt over 
total Akt protein levels in the Gas muscle of WT, mdx Veh, mdx AICAR and mdx Met mice. Relative quantities 
are normalized to either alpha-tubulin or vinculin (n=3; P<0.05). *compared to mdx Vehicle. ±STDEV are 
shown. 
we compared the expression of utrophin in the slow muscle of wild-type and mdx mice 
carrying the fast-muscle-specific Ca2+ buffering protein parvalbumin, to that in wild-type and 
mdx non-transgenic ones. Our data shows that directed expression of PV in slow fibres 
significantly decreases the utrophin content of the muscle in PV and mdx/PV transgenic 




















Fig. 7 Alterations of Ca2+ kinetics by forced expression of PV in slow fibres down-regulate utrophin through 
Cn/NFAT signalling. Representative immunoblot (A and C) and quantification for B) utrophin, D) RYR1, E) 
SERCA1, F) SERCA2, G) SLN, and H) PLN protein levels in the Sol muscle of WT, PV, mdx, and mdx/PV mice. 
Relative quantities are normalized to vinculin (n=3; P<0.05). *compared to mdx, #compared to WT. ±STDEV are 



















 In order to track the changes upstream of the pathway due to the introduction of PV, 
we sought to investigate the expression and activity of the SR Ca2+ handling proteins. Our 
results for this purpose suggest no change in the expression of either isoforms of SERCA (i.e. 
SERCA1 and 2) Ca2+ uptake channels, while the inhibitors of these channels, sarcolipin and 
phospholamban, were remarkably decreased (Fig. 7E-H). In contrast, the Ca2+ release 
channel, ryanodin receptor, was down-regulated (Fig. 7D). 
5.3 - Expression pattern of HSP70 under direct and indirect manipulation of Cn/NFAT 
signalling pathway  
 For years, up-regulation of utrophin as a compensator for the absence of dystrophin 
has been the main area of the focus to improve the impaired pathology of the muscle in 
DMD. In our lab, this objective has been shown to be achievable through the promotion of 
the slow oxidative myogenic program via the Cn/NFAT pathway7. These adaptive changes in 
the slow phenotype regulation is known to be correlated with increasing levels of HSP7080. 
Nevertheless, a recent study gives strong evidence that the up-regulation of HSP70 alone 
ameliorates the dystrophic phenotype independent of utrophin63. Accordingly, we were 
curious to see if HSP70 is regulated via Cn/NFAT signalling. Hence, we probed for HSP70 in 
mice who overexpress either PV (i.e. upstream manipulation of any Ca2+-dependent 
pathway) or CnA* (i.e. direct manipulation of Cn/NFAT signalling). This experimental 
strategy not only could reveal if the expression of HSP70 is directly influenced by Cn/NFAT 
signalling, but also It could give us the ability to see if HSP70 is in fact regulated via any 
mechanisms dependent on Ca2+ signalling in the first place. Moreover, it could give us the 
ability to further confirm that utrophin is regulated via Cn/NFAT signalling and as a result 
any alterations in Ca2+ homeostasis would affect its expression. Accordingly, our data 
showed down-regulation of HSP70 in parallel with utrophin in PV and mdx/PV crossbreds, 
despite no changes of it in mdx/CnA* transgenic mice where utrophin is up-regulated due to 












Fig. 8 Regulation of HSP70 is a Ca2+-dependent process independent of Cn/NFAT signalling pathway. HSP70 is 
down-regulated in PV mice, while it is unchanged in mice carrying a constantly active form of Cn (i.e. CnA*). In 
contrast, utrophin undergoes significant changes in both cases. Representative immunoblot (A and B) and 
quantification for C-D) utrophin and E-F) HSP70 protein levels in WT, PV, mdx, mdx/PV, and mdx/CnA* mice. 
Sol and EDL muscles were used for the PV and the CnA* experiments, respectively. Relative quantities are 














6.1 - AICAR and Metformin drugs decrease the activity of calcineurin 
 AMPK is one of the enzymes that can sense and restore the energy levels of the cell 
in response to energy homeostasis-related signals44. The AMPK signaling led by this enzyme 
can be pharmacologically promoted by administration of AICAR, the activator of AMPK 
pathway. Our collaborators in Ottawa have previously shown that treating mice with 500 
mg/kg/day of AICAR for four weeks induces the expression of the markers for slow, 
oxidative myogenic program through the AMPK pathway48. As a result of this induction, the 
central localization of nuclei was decreased and the integrity of sarcolema was enhanced 
during contraction-induced damages48. This was also associated with a significant increase 
(i.e. up to two-fold) in utrophin levels of EDL muscle compared to wild-type48. However, this 
raised the question of whether these pathological adaptations were due to more utrophin 
content, or because of the increased expression of slow fibre markers. Therefore, a few 
years later, they compared utrohpin-dystrophin DKO mice with mdx under AICAR treatment, 
and observed that despite similar changes in the expression of slow fibre markers, DKO mice 
which lack utrophin were unable to improve the integrity of the sarcolema and showed 
more signs of damage compared to mdx-treated mice. This indicated the crucial role of 
utrophin in the improvement of dystrophic pathology following the pharmacological 
induction of the slow myogenic program78. On the other hand, our lab has shown that 
utrophin expression is regulated in part by Cn/NFAT signalling, meaning that the constant 
activation of Cn in fast fibres eventually leads to increased levels of utrophin in the muscle43. 
In light of this, we were curious to find out if the up-regulation of utrophin in the AICAR 
treatment study had anything to do with Cn/NFAT signalling. Accordingly, proteins from the 
gastrocnemious muscles of the same treated mice in that study were isolated and subjected 
to western blot analysis. Our immunoblot experiments showed a decreased expression of 
NFATc1, despite no changes in Cn and Cn inhibitor (i.e. RCAN1.4) levels (Fig. 5C-H). Aside 
from this, the down-regulation of NFATc1 was in accordance with a lower active 
(phosphorylated) form of GSK3β (Fig. 5A-B), the protein that reverses the nuclear 
translocation of NFATcs. This can suggest that the pharmacological promotion of a slow, 
oxidative program through the AMPK pathway is achieved in part by a reduction of the 
activity (not expression) of Cn. 
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 Lower activity of Cn was associated with a decreased expression of utrophin (Fig. 5J), 
which is in agreement with our previous findings77. However, it is contrary to the findings of 
our collaborators, where induction of the AMPK pathway led to an increase in utrophin in 
relation with promoted slow myogenic program78. One possible explanation for this 
contradiction could be the differences between the muscles used in each study - in theirs, 
they analyzed the EDL muscle of mice, while we analyzed the Gas muscles. The fibre-type 
composition of these muscles are highly different - EDL is mainly composed of pure fast 
fibres (i.e. only ~5 percent Type 1 slow), while Gas muscles can have up to ~20 percent slow 
fibres supplemented with slower fast hybrid fibres81. Moreover, the transition of EDL’s 
highly glycolytic fast fibres to a slower type of fibre under AICAR treatment may act in a 
muscle-specific manner and consequently affect the fibre type composition of other 
muscles (detailed studies for such a hypothesis is definitely required). Our results show the 
same pattern of expression of the Cn/NFAT signaling players for the Metformin-treated 
mice identical to those of the AICAR treatment, and therefore also contrary to the 
unpublished data of our collaborators where utrophin was up-regulated.      
6.2 - Slow fibre-directed expression of PV in mdx mice decreases the Cn/NFAT signalling  
 Intracellular Ca2+ oscillations are not alike between different muscle types. This is 
due to the differences in the volume of Ca2+ influx in response to different patterns of 
contraction impulses in fast and slow fibres82,83. One of the main calcium buffering proteins 
specific to fast fibres is parvalbumin (PV)84. Forced expression of PV in slow fibres has been 
shown to reduce the oxidative capacity of the muscle in association with a significant 
decrease in Cn activity75. On the other hand, [Ca2+]i levels are higher in dystophic cases than 
normal50,51. In light of these facts, we hypothesized that directed expression of the fast-
fibre-specific PV in the slow fibres of mdx will also lead to a similar reduction of Cn activity, 
and as a result, decrease the expression of utrophin, which will eventually exacerbate the 
dystrophic pathology. Signs of severe damage to muscle fibres have been confirmed in our 
lab by measuring the central localization of the nuclei (unpublished data). Our results 
confirm the aforementioned hypothesis and further approve that any fluctuations in the 
activity of Cn/NFAT, whether caused by direct targeting of the pathway's elements or 
indirectly through changes in the calcium homeostasis, eventually affect the expression of 
utrophin (Fig. 7B).   
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6.3 - Cytosolic Ca2+ levels controlled by SR channels determine the activity rate of calcineurin 
 Muscle contraction and relaxation are in direct concomitance with the Ca2+ levels of 
cytosol. When contraction is about to happen, extracellular Ca2+ entry to the cytosol triggers 
Ca2+ release from SR to cytosol through ryanodin receptor channels85. This leads to a sudden 
increase in the concentration of cytosolic calcium85. Once the contraction is over and the 
muscle goes back to its relaxed state, this concentrated cytosolic Ca2+ needs to be reuptake 
into the SR85,86. This necessity is fulfilled by the SERCA channels86. In DMD cases, cytosolic 
Ca2+ levels are naturally higher regardless of the contraction/relaxation state of the muscle, 
which although it leads to the upregulation of utrophin through Cn/NFAT signalling, can also 
have its own detrimental consequences (e.g. activation of necrotic proteases)57,58. Here in 
this study, by introducing a fast fibre-specific Ca2+-buffering protein (PV) to the slow fibres 
of mdx mice, we have shown that utrophin is down-regulated, indicating that Cn/NFAT 
signalling is highly affected by cytosolic Ca2+ levels (Fig. 7B). On the other hand, the 
reduction of cytosolic Ca2+ is in coordination with the activity levels of SR calcium 
channels86. Accordingly, since the calcium oscillation of slow fibres in mdx/PV mice forcedly 
mimics that of fast fibres, we can see that despite the unchanged expression of SERCA 
channels, their activity is less inhibited due to the decreased expression of sarcolipin (SLN) 
and phospholamban (PLN), the inhibitors of SERCAs (Fig. 7E-H). 
 It is shown that the inhibition of the expression of ryanodin receptor 1 in fast fibres 
triggers a fast-to-slow fibre type transition87. Interestingly, our data shows a decrease in the 
expression of RYR1 in mdx/PV mice (See fig. 7D), while the fast fibre-specific SERCA1 
expression was not changed.  When both are together, this may indicate the attempt of the 
fibres to maintain their slow-oxidative capacity when PV, and as a result, a faster fibre type 
status, is imposed on them. Moreover, the decrease in SERCA2 is an mdx effect and PV 
independent, since its expression level is almost identical between mdx and mdx/PV. 
However, supporting this interpretation requires the assessment of the expression and 
activity of L-type Ca2+ channels of sarcolemma as well.  
 SLN and PLN, the inhibitors of SERCA channels, were down-regulated in mdx/PV 
compared to mdx, indicating higher activity of SERCA channels, and as a result, more 
prevention of the Cn/NFAT pathway from cytosolic Ca2+. 
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 Our results for the AICAR and Metformin-treated mice also show a great reduction in 
the expression of SLN despite no changes in the expression of SERCA and RYR1 channels 
(See fig. 6B-E) indicative of higher overall activity of SERCA. As a result, there is more 
reuptake of Ca2+, leading to less cytosolic Ca2+, and consequently, decreasing Cn/NFAT 
signalling. In addition to this, phosphorylated Akt over total Akt was also decreased, which 
has further resulted in less phosphorylated SLN, and consequently, less inhibition of SERCAs 
(Fig. 6F).    
 The data obtained by these two strategies (MDX/PV and mice treatments with the 
aforementioned drugs) suggests that [Ca2+]i homeostasis which is intrinsically correlated 
with the activity and expression of SR calcium handling proteins determines the rate of the 
activity (not the expression) of Cn in the very upstream part of the pathway, therefore 
affecting the expression of Cn/NFAT signalling-regulated proteins. Therapeutically, this 
could be of great importance for strategies aimed towards up-regulating utrophin in 
dystrophic myopathy studies. 
6.4 - HSP70 expression is affected by cytosolic Ca2+ levels independent of Cn/NFAT signalling 
 The HSP family of proteins has been shown to revive some proteins of the 
cytoskeleton, such as actin and cytosolic membrane channels, as a result of mechanical 
damage to the fibres in dystophic conditions63,72. Furthermore, HSP70 is shown to be 
expressed more in the soleus where there are more type 1 slow oxidative fibres available 
than in the faster-glycolytic plantaris, suggesting a correlation between the oxidative 
capacity of the muscle and its regenerative power80. Recently, scientists could prove the 
protective role of HSP70 over SERCA channels, resulting in the amelioration of dystrophic 
phenotype independent of utrophin up-regulation63. Accordingly, it was in the interests of 
our lab to assess the pattern and relevance of the expression of utrophin and HSP70 in a 
Cn/NFAT signalling-oriented approach, so we examined their expression under directly and 
indirectly altered Cn/NFAT signalling conditions. Interestingly, we observed that the 
expression of HSP70 was decreased when cytosolic Ca2+ levels of slow fibres were decreased 
(i.e. PV and mdx/PV mice), and was not changed when Cn/NFAT signalling was constitutively 
activated (i.e. mdx/CnA* mice) (Fig. 8). This strongly suggests that the regulation of HSP70 is 
a Ca2+-dependent procedure independent of Cn/NFAT signalling pathway.  
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7. CONCLUSION 
 In summary, we have managed to use three different approaches to add new 
findings to our current understanding of Cn/NFAT signalling activity alterations in 
association with intracellular Ca2+ homeostasis. This was achieved by immunoblot analysis 
of Cn/NFAT signalling-involved factors and SR Ca2+ handling channels in mdx mice over-
expressing either a Ca2+ buffering protein, parvalbumin, or a constitutively active form of Cn 
(CnA*). Aside from this, the analysis of mdx mice treated with AMPK pathway activators, 
AICAR, and Metformin as a complementary approach not only helped in understanding the 
process, but also led to another novel finding. First and foremost, our results suggest that 
the upstream determiner of the activity alterations of Cn/NFAT signalling and potentially 
other Ca2+-dependent pathways is the quantity and activity rate of the SR Ca2+ handling 
channels, since forced cytosolic calcium changes in mdx/PV could down-regulate utrophin 
similarly to our previous findings where direct interference with Cn/NFAT signalling by a 
calmodulin binding protein (CaMBP) also led to the down-regulation of utrophin77. 
Secondly, by comparing the expression of utrophin and HSP70 in mdx/PV and mdx/CnA*, 
we could infer that HSP70 is regulated by a Ca2+-dependent pathway rather than Cn/NFAT, 
since its expression was changed in mdx/PV mice but remained intact in mdx/CnA* mice. 
Finally, we observed that the administration of AICAR and Metformin, which is known to 
activate the AMPK pathway, can reduce the activity of Cn. Whether this is a direct effect or 
a result of AMPK up-regulation, it needs further detailed analysis. Collectively, these results 
have a great potential for future elucidations of molecular therapeutic approaches toward 
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